nach oben

Arthritis Research & Therapy

Erschienen in:

01.03.2005 | Review

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis

verfasst von: Eric M Ruderman, Richard M Pope

Erschienen in: Arthritis Research & Therapy | Sonderheft 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Abatacept (CTLA4–Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28–CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.

Keystone EC: Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol. 2003, 15: 253-258. 10.1097/00002281-200305000-00012.CrossRefPubMed

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, et al: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46: 1470-1479. 10.1002/art.10294.CrossRefPubMed

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349: 1907-1915. 10.1056/NEJMoa035075.CrossRefPubMed

Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991, 147: 2461-2466.PubMed

Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001, 19: 225-252. 10.1146/annurev.immunol.19.1.225.CrossRefPubMed

Verwilghen J, Lovis R, De Boer M, Linsley PS, Haines GK, Koch AE, Pope RM: Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol. 1994, 153: 1378-1385.PubMed

Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA: CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 1996, 184: 783-788. 10.1084/jem.184.2.783.CrossRefPubMed

Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996, 183: 2541-2550. 10.1084/jem.183.6.2541.CrossRefPubMed

Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA: Cutting Edge: CD28 controls peripheral homeostasis of CD4+, CD25+ Regulatory T cells. J Immunol. 2003, 171: 3348-3352.CrossRefPubMed

10.

Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991, 174: 561-569. 10.1084/jem.174.3.561.CrossRefPubMed

11.

Walunas TL, Bluestone JA: CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol. 1998, 160: 3855-3860.PubMed

12.

Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science. 1994, 265: 1225-1227.CrossRefPubMed

13.

Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol. 1995, 154: 1481-1490.PubMed

14.

Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 1995, 95: 2783-2789.PubMedCentralCrossRefPubMed

15.

Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD: A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol. 2000, 164: 136-143.CrossRefPubMed

16.

Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ: Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995, 96: 987-993.PubMedCentralCrossRefPubMed

17.

Daikh DI, Wofsy D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001, 166: 2913-2916.CrossRefPubMed

18.

Tada Y, Nagasawa K, Ho A, Morito F, Ushiyama O, Suzuki N, Ohta H, Mak TW: CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol. 1999, 162: 203-208.PubMed

19.

Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, Gawronska-Szklarz B: The expansion of CD4⁺ CD28^- T cells in patients with rheumatoid arthritis. Arthritis Res Ther. 2003, 5: R210-R213. 10.1186/ar766.PubMedCentralCrossRefPubMed

20.

Weinblatt M, Schiff M, Goldman M, Kremer J, Breazna A, Becker JC: A pilot, multi-center, randomized, double-blind, placebo controlled [study] of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum. 2002, S204-Suppl

21.

Emery P, Russell A, Kremer J, Williams GR, Li T, Nuamah I, Becker JC, Weisman MH: Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a selective co-stimulation modulator, over one year in patients with active rheumatoid arthritis using methotrexate [abstract]. Arthritis Rheum. 2003, S4-Suppl

22.

Emery P, Westhovens R, Moreland L, Nuamah I, Aranda R, Becker J, Kremer J: CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methotrexate showed correlation between the clinical response and key biomarkers [abstract]. Presented at: European League Against Rheumatism Annual Meeting, Lisbon, Portugal. 2003, [http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2003SCIE-abstract&TEMPLATE=&keyf=0896&showHide=show&client=]

23.

Kremer J, Shergy W, Tindall E, Aranda R, Nuamah I, Zhou Y, Becker JC: Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S182-Suppl

24.

Dougados M, Weswthovens R, St Clair EW, Aranda R, Nuamah I, Zhou Y, Vratsanos G, Becker JC: Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S185-Suppl

25.

Moreland L, Weisman M, Alten R, Aranda R, Zhou Y, Wu K, Nuamah I, Becker JC: Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years [abstract]. Arthritis Rheum. 2004, S563-Suppl

26.

Kremer J, Westhovens R, Moreland L, Emery P, Russell A, Ge Z, Aranda R, Becker JC: Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in INadequate responders to Methotrexate) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX. 2004, [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={85C06A69-418B-47A1-BEF0-F919C8C4F640}&MKey={6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey={AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey={8FF4FA39-962F-41CF-B617-5E132EB117E5}]

27.

Genovese MC, Luggen M, Schiff M, Sherrer Y, Nuamah I, Aranda R, Becker JC, Dougados M: Efficacy and safety of abatacept (CTLA4Ig), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-a[ED:alpha] therapy: results of the phase III ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate responders) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX. 2004, [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={460C7526-77D4-4A49-AD2D-440A2515EE22}&MKey={6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey={AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey={100FBD25-6760-48B9-A4F5-EEEE63E1DAAA}]

Titel: The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
verfasst von: Eric M Ruderman
Richard M Pope
Publikationsdatum: 01.03.2005
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe Sonderheft 2/2005
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1688

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen